Acadia Pharmaceuticals (ACAD) Short term Debt (2010 - 2012)

Acadia Pharmaceuticals' (ACAD) quarterly Short term Debt came in at $22000.0 in Q1 2012, down 31.25% quarter-over-quarter from $32000.0 in Q4 2011.

Acadia Pharmaceuticals (ACAD) Short term Debt (2010 - 2012) Analysis & Trends

Acadia Pharmaceuticals' Short term Debt history runs 3 years deep, the most recent figure standing at $22000.0 for Q1 2012.

  • On a quarterly basis, Short term Debt changed N/A year-over-year to $22000.0 in Q1 2012; TTM through Mar 2012 was $22000.0, a N/A change from a year earlier, with the FY2011 full-year figure at $32000.0, down 58.97% from the prior year.
  • Short term Debt slipped to $22000.0 in Q1 2012 per ACAD's latest filing, from $32000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $78000.0 in Q4 2010 and bottomed at $22000.0 in Q1 2012.
  • The 3-year median for Short term Debt is $37000.0 (2011), against an average of $41800.0.
  • Biggest YoY gain for Short term Debt was 58.97% in 2011; the steepest drop was 58.97% in 2011.
  • Year by year, Short term Debt stood at $78000.0 in 2010, then sank by 58.97% to $32000.0 in 2011, then tumbled by 31.25% to $22000.0 in 2012.
  • Per Business Quant, the three latest ACAD Short term Debt figures stand at $22000.0 (Q1 2012), $32000.0 (Q4 2011), and $37000.0 (Q3 2011).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Acadia Pharmaceuticals 4.23 Bn 3.38 Bn 243.27 Mn

Historic Data

Download Data
DateValue
Mar 31, 2012 22,000.00
Dec 31, 2011 32,000.00
Sep 30, 2011 37,000.00
Jun 30, 2011 40,000.00
Dec 31, 2010 78,000.00